Abstract
Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and been linked to ongoing clinical trials. Molecular stratification of patient groups will clearly be critical to successful drug development and clinical trials from the view point of precision medicine. In this review, we discuss the potential of new targeted approach to impact the clinical management of CRPC.
| Original language | English |
|---|---|
| Title of host publication | Hormone Therapy and Castration Resistance of Prostate Cancer |
| Publisher | Springer Singapore |
| Pages | 375-385 |
| Number of pages | 11 |
| ISBN (Electronic) | 9789811070136 |
| ISBN (Print) | 9789811070129 |
| DOIs | |
| Publication status | Published - 2018 May 11 |
Fingerprint
Keywords
- AR signaling pathway
- Cell-free DNA
- Circulating tumor cells
- CRPC
- DNA repair pathway
- Liquid biopsy
- PI3K-PTEN-AKT-mTOR pathway
- Precision medicine
- WNT pathway
ASJC Scopus subject areas
- Medicine(all)
Cite this
New targeted approach to CRPC. / Kosaka, Takeo; Oya, Mototsugu.
Hormone Therapy and Castration Resistance of Prostate Cancer. Springer Singapore, 2018. p. 375-385.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - New targeted approach to CRPC
AU - Kosaka, Takeo
AU - Oya, Mototsugu
PY - 2018/5/11
Y1 - 2018/5/11
N2 - Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and been linked to ongoing clinical trials. Molecular stratification of patient groups will clearly be critical to successful drug development and clinical trials from the view point of precision medicine. In this review, we discuss the potential of new targeted approach to impact the clinical management of CRPC.
AB - Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and been linked to ongoing clinical trials. Molecular stratification of patient groups will clearly be critical to successful drug development and clinical trials from the view point of precision medicine. In this review, we discuss the potential of new targeted approach to impact the clinical management of CRPC.
KW - AR signaling pathway
KW - Cell-free DNA
KW - Circulating tumor cells
KW - CRPC
KW - DNA repair pathway
KW - Liquid biopsy
KW - PI3K-PTEN-AKT-mTOR pathway
KW - Precision medicine
KW - WNT pathway
UR - http://www.scopus.com/inward/record.url?scp=85053172302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053172302&partnerID=8YFLogxK
U2 - 10.1007/978-981-10-7013-6_38
DO - 10.1007/978-981-10-7013-6_38
M3 - Chapter
AN - SCOPUS:85053172302
SN - 9789811070129
SP - 375
EP - 385
BT - Hormone Therapy and Castration Resistance of Prostate Cancer
PB - Springer Singapore
ER -